INTERVIEW The Next Big Sector? Brian Lazorishak discusses sector rotation and shares the reasons for why he is currently looking to stay defensive on sectors such as consumer staples and healthcare.

INTERVIEW Find Good Managers and You Will Find Good Funds Jeff DeMaso of Advisor Investments outlines the company's long-term approach to the markets and strategy of finding good fund managers.

INTERVIEW Janet Brown: Global, Mid-Cap, Tech Funds Janet Brown at MoneyShow Las Vegas top sectors: we're seeing international funds, global funds, mid-cap funds. Move incrementally. You're putting money into what's working.

INTERVIEW Hilary Kramer's 3 GameChanger Stocks Hilary Kramer's 3 stock ideas: Calavo Growers (CVGW), avocado producer. Nvidia (NVDA) for graphics processing for gaming, pros. GW Pharmaceuticals (GWPH) for imedical marijuana therapeutics.

SPEAKER Silverman, Jay Jay Silverman has been a biotechnology and pharmaceuticals analyst for over 25 years and has a tremendous track record in analyzing and recommending biotech stocks.

In 2000, he was ranked #1 in Biotechnology by The Wall Street Journals Best on the Street annual analyst survey, in addition to being a Home-Run Hitter for stock selection. As an analyst, he was frequently quoted in The Wall Street Journal, TIME, Fortune and featured on CNBC and CNN.

From 2010-2012, Jay was Vice President Business Development for Thorne Research, a leading natural products company. From 2007-2010, he was Vice President, Strategic Development for Diversified Natural Products (DNP), which merged with Thorne Research in June 2010.

From 2003-2005, Mr. Silverman was a Partner in charge of healthcare investments at Colonial Fund, LLC, a New York-based hedge fund. Jay is also President of COLS Consulting.

From 1997-2001, he was a Managing Director, Senior Biotechnology Analyst for Robertson, Stephens, a leading biotech/technology investment bank. Prior to that (1992-1997), Mr. Silverman was Senior Biotech and Medical Technology Analyst for Schroeder Wertheim. From 1987-1992, he was Senior Biotechnology and Pharmaceuticals Analyst for Nomura Research Institute.

Mr. Silverman graduated from the University of Pennsylvanias Wharton School in 1987 with a B.S. in Economics/Finance.

SPEAKER Salvagno, Ralph Dr. Ralph Salvagno is chairman of the Board and CEO of Petlife Pharmaceuticals and a practicing orthopaedic surgeon. He brings his scientific background, business acumen, and love of pets to the challenge of cancer treatment in our companion animals.

INTERVIEW The Election and its Effect on the Healthcare Sector Bryan Perry expects to see weakness within the healthcare sector until mid-September and is favorable on big name biotech

INTERVIEW Biotech & Home Builder Stocks to Watch Bret Jensen believes that the biotech sector is in the biggest bear market in the industry's history and sees value in the biotech and home-building sectors.

INTERVIEW Love the Sector Everyone Hates Biotech expert Bret Jensen shares his reasons as well as some of his top picks in this most hated, most oversold, but also most potentially profitable sector in the market.

INTERVIEW Momentum Strategy for Finding Beaten-Down Sectors Sector rotation occurs quicker these days, so Jackie Ann Patterson takes a technical look at a safe haven sector in the midst of the stock market's downtrend.